Report from Brazil - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Report from Brazil
Brazil's major vaccine producer innovates with stem-cell research.


Pharmaceutical Technology
Volume 37, Issue 3, pp. 34-36

In 1898, an outbreak of Bubonic plague struck the port of Santos in São Paulo, Brazil. A year later, a local bacteriological institute set up a unit to produce anti-plague serum in a government-owned farm known as Butantan, which was renamed the Butantan Serumtherapy Institute in 1901.


NASH PHOTOS/GETTY IMAGES
The institute started gaining global recognition as it ventured into research on animal venom, which consequently led to the production of anti-venom. In 1915, the institute was renamed Butantan Institute. Known as Butantan, the institute currently conducts technical and scientific activities in two major areas—the production of serum and biomedical research.

The institute claims to be Latin America's biggest vaccine producer, with an output of more than 300 million doses every year. Today, Butantan is considered a major contributor to Brazil's public health, having approximately 1700 staff members, including 180 scientific researchers specializing in innovation.

Innovation using Brazilian technology

"I believe Butantan Institute is an important partner to [Brazil's pharma] companies as 80% of all vaccines used in Brazil are produced by this institute," says Irina Kerkis, director of the genetics laboratory at Butantan Institute. Despite its struggles in a globally competitive market, the institute reaches for innovation while balancing research and production according to its researchers.

In its search for local and global recognition, Butantan has developed major research capabilities at its genetics laboratory, including the expertise to retrieve stem cells from milk teeth. Nelson Foresto Lizier, a scientific researcher working at Butantan's genetics laboratory, says that this project is vital given that stem cells have the ability to generate almost any human cell. The study, which is considered the first of its kind in Brazil, is being developed with "100% Brazilian technology" according to Lizier.

The development of the technology started in 2004. It was initially privately funded; however, six years later, investment from major public agencies began pouring in according to Kerkis.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
27%
Breakthrough designations
9%
Protecting the supply chain
41%
Expedited reviews of drug submissions
9%
More stakeholder involvement
14%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests
Source: Pharmaceutical Technology,
Click here